Nkarta, Inc. (NKTX): restructuring charge — Nkarta gets FDA IND clearance for NKX019 in LN; cuts workforce 10%, extends cash runway

Nkarta, Inc.

FDA cleared IND for NKX019 (CAR NK) for lupus nephritis; enrollment starts H1 2024; up to 12 patients.
RIF of 18 employees (~10% workforce); $1M-$1.5M severance costs in Q4 2023; extends cash runway into 2026.
Preliminary cash $278.4M as of Sep 30, 2023; cash runway extended one year into 2026.
NKX019 NHL: new compressed dosing cohort (Days 0,3,7) for LBCL; prior expansion cohorts discontinued.
Clinical updates in 2024: NKX101 AML H1, NKX019 NHL mid-2024, NKX019 LN in 2024.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.95

Nkarta, Inc. announced a restructuring with charges of approximately $1 million to $1.5 million affecting Reduction in force of 18 positions, representing approximately 10% of the Company's workforce (reduction of 18 positions).

Type: restructuring
Charge: approximately $1 million to $1.5 million
Affected area: Reduction in force of 18 positions, representing approximately 10% of the Company's workforce
Headcount: reduction of 18 positions

Exact text from the filing

to extend the Company’s cash runway by one year into 2026. In connection with the implementation of the Reduction, the Company currently estimates it will incur approximately $1 million to $1.5 million in costs, consisting primarily of cash severance costs and transition support services for impacted employees, which the Company expects to recognize in the

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-053645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.